#United States #MedTech #Labcorp #Toledo, Ohio #NAMSA

NAMSA Completes Strategic Acquisition of Labcorp’s Early Development Medical Device Testing Business

In a significant move for the medical device testing sector, NAMSA, a prominent global leader in clinical research and regulatory consulting, has announced the successful acquisition of select assets from Labcorp's Early Development medical device testing business. This strategic decision reflects NAMSA's relentless dedication to fostering innovation and improving timelines for MedTech manufacturers on a worldwide scale.

This acquisition is an important milestone for NAMSA, as it now assumes responsibility for a comprehensive portfolio of services tailored for medical device development, previously managed by Labcorp. The U.S. services of Labcorp's Early Development testing include critical functions such as biocompatibility and microbiological testing, analytical analysis, and preclinical research, all vital for ensuring the safety and effectiveness of medical devices.

Brian Smith, NAMSA's CEO, expressed enthusiasm about the acquisition, stating, "This acquisition is a perfect fit for NAMSA. We serve over 3,000 MedTech clients globally in these areas of testing and preclinical research. I am confident that we can deliver Labcorp's medical device clients a transition that maintains the high-level expertise and customer service they expect."

With this acquisition, NAMSA solidifies its position as a comprehensive partner for medical device development. By expanding its portfolio, NAMSA can offer clients enhanced expertise and streamlined solutions that cover the entire product lifecycle, from initial testing through to regulatory approval.

The integration will take place across NAMSA's established facilities located in Ohio, Minnesota, Georgia, and California, where future testing and preclinical projects for Labcorp's former clients will be conducted. This detailed plan aims to ensure that there are no disruptions to ongoing projects and that all clients continue to receive exceptional service.

Labcorp's decision to sell its Early Development medical device testing business aligns with its strategic focus on core competencies in preclinical drug development and chemical testing. Brian Caveney, M.D., who serves as the EVP and President of Early Development Research Laboratories at Labcorp, commented, "The sale of our Early Development medical device testing business to NAMSA allows Labcorp to concentrate on its primary areas of expertise. We are confident that NAMSA will provide the high-level expertise our former clients expect, ensuring a seamless transition."

As an ARCHIMED company since 2020, this acquisition marks the tenth strategic acquisition for NAMSA, demonstrating its aggressive growth trajectory and commitment to enhancing its service offerings in the healthcare sector.

NAMSA has built a solid reputation as a vital partner for medical device sponsors striving for success in the market since 1967. The firm is renowned for its testing services, clinical trials, and regulatory consulting, having carved out a niche in the fast-evolving landscape of medical technology. With expertise across various therapeutic areas, NAMSA is well-equipped to facilitate efficient medical device product development and regulatory compliance.

Looking ahead, the implications of this acquisition are profound. It not only enhances NAMSA's capabilities but also signifies an unwavering commitment to advancing the medical device industry, making it easier for innovators to get their products to market. For those in the MedTech field, this acquisition could mean faster, more reliable testing and research services, paving the way for groundbreaking medical innovations in the years to come.

For anyone looking to learn more about NAMSA's extensive services, their operational footprint in the U.S., Europe, and Asia, and their commitment to medical device development, further details can be found on their official website at namsa.com.

In conclusion, NAMSA's acquisition of Labcorp's Early Development medical device testing assets exemplifies how strategic growth initiatives can significantly impact the MedTech landscape, ultimately driving innovation and improving health outcomes across the globe.